Efficacy and tolerance of interferon-alpha in the treatment of chronic Hepatitis C in end-stage renal disease patients on hemodialysis

Efficacy and tolerance of interferon-alpha in the treatment of chronic Hepatitis C in end-stage renal disease patients on hemodialysis

Autor Rocha, C. M. Google Scholar
Perez, R. M. Google Scholar
Ferreira, A. P. Google Scholar
Carvalho-Filho, R. J. Google Scholar
Pace, F. H. Google Scholar
Silva, I. S. Google Scholar
Pestana, JOM Google Scholar
Lanzoni, V. P. Google Scholar
Silva, A. E. Google Scholar
Ferraz, MLG Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Background: Patients with end-stage renal disease (ESRD) show a high prevalence of hepatitis C, with a negative impact on the survival on hemodialysis and after renal transplantation. We evaluated the efficacy and tolerance of interferon-alpha (IFN-alpha) in HCV-infected ESRD patients on dialysis. Methods: Forty-six HCV-RNA-positive ESRD patients were studied. IFN-alpha regimen consisted of 3 million units three times a week for 12 months, and the patients were followed up for 6 months. End-of-treatment, and sustained biochemical and virological responses were evaluated and tolerance was assessed monthly. Results: A sustained virological response (SVR) was observed in 10/46 patients (22%) and in 10/29 who completed the treatment (34%). Alanine aminotransferase was elevated in 63% of the patients at the beginning of the study and returned to normal levels within the first month in all patients with SVR. Treatment was discontinued because of side effects in 11/46 patients (24%) and six patients (13%) were lost to follow-up. Conclusions: IFN-alpha monotherapy for hepatitis C in dialysis patients shows a high frequency of adverse effects. However, the SVR is high (34%) in patients who complete treatment, emphasizing the importance of careful selection and close follow-up in order to minimize and control possible side effects.
Palavra-chave end-stage renal disease
hemodialysis
hepatitis C
interferon-alpha
liver
side effects
Idioma Inglês
Data de publicação 2006-04-01
Publicado em Liver International. Oxford: Blackwell Publishing, v. 26, n. 3, p. 305-310, 2006.
ISSN 1478-3223 (Sherpa/Romeo, fator de impacto)
Publicador Blackwell Publishing
Extensão 305-310
Fonte http://dx.doi.org/10.1111/j.1478-3231.2005.01225.x
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000235868000006
Endereço permanente http://repositorio.unifesp.br/handle/11600/28837

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta